jueves, 1 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· June 24, 2026

Paychex outlines FY 2027 outlook with 5%-6% revenue growth and ~44% adjusted operating margin

View original at seekingalpha.com

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • FY2027 adjusted operating income margin is expected to be approximately 44%, effective tax rate approximately 24%, adjusted diluted EPS growth 7% to 9%, and Q1 adjusted operating margin 41% to 42%.

    60% confidence
  • Paychex exited fiscal 2026 with strong momentum, citing double-digit revenue and earnings growth in the fourth quarter and full year, with accelerating organic revenue growth each quarter.

    60% confidence
  • WISE is Paychex's AI-powered intelligence engine powering approximately 600 AI features and agents, drawing on more than 26 trillion data points.

    60% confidence
  • Q4 total revenue increased 12% over the prior year to $1.6 billion, with Management Solutions revenue up 14% to $1.2 billion and PEO and Insurance Solutions revenue up 9% to $370 million.

    60% confidence
  • Paychex exceeded its fiscal 2026 synergy targets from the Paycor acquisition, with over 50 basis points of revenue-growth contribution and over $100 million in cost synergies, and is winning larger deals than anticipated.

    60% confidence
  • Paychex returned $2.2 billion to shareholders through $1.6 billion in cash dividends and $600 million in share repurchases, and reduced leverage by 0.5 turn, including repayment of the initial $400 million Oasis acquisition debt tranche.

    60% confidence
  • Interest on funds held for clients is expected to be in the range of $195 million to $205 million, declining due to prior rate cuts and lapping one-time portfolio repositioning gains, assuming no further Fed funds rate changes.

    60% confidence
  • Paychex's client base is relatively flat, with growth driven by an increase in revenue per client.

    60% confidence
  • Health care cost inflation is unsustainable for small and mid-sized businesses, acting as a double-edged sword that pressures affordability while supporting PEO demand.

    60% confidence
  • Q4 interest on funds held for clients grew 15% to $52 million; operating income margin increased approximately 750 basis points to 37.7%; adjusted operating income margin increased approximately 170 basis points to 42.1%; diluted EPS increased 43% to $1.17; adjusted diluted EPS increased 11% to $1.32.

    60% confidence
  • Fiscal 2027 total revenue growth is guided in the range of 5% to 6%, Management Solutions revenue growth 5% to 6%, and PEO and Insurance Solutions revenue growth 6% to 7%.

    60% confidence
  • Midterm organic growth is typically 7% to 8%, with M&A adding 1% to 2%, and no acquisition on the scale of the Paycor deal is expected near-term.

    60% confidence
  • Paychex is already generating AI revenue, with about 10,000 customers in a timekeeping AI soft launch that is cutting errors by roughly 70% upfront.

    60% confidence
  • PEO strength includes record worksite employee retention, while the insurance agency continues to be a drag though some positive trends are emerging.

    60% confidence
  • Fiscal 2026 total revenue increased 17% over the prior year to $6.5 billion, operating cash flow increased 35% to $2.6 billion, and free cash flow increased 36% to $2.3 billion.

    60% confidence
  • PEO remains a key growth driver, with worksite employee growth outpacing the industry at high single-digit rates in the quarter and full year.

    60% confidence
  • Client retention for 100-plus employee accounts is the highest it has been in Gibson's 13 years at the company, and Paychex will not do irrational things to boost client counts.

    60% confidence
  • Asked whether Paychex could size how much of the apparent Paycor deceleration is revenue shifting rather than true slowdown.

    60% confidence

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,317 documentos fuente archivados
Consulta estos datos → isubstrate.com